Asthma/Airway hyperactivity symptoms. Combination of Nonallergic asthma and allergic asthma
Conditions
Interventions
12 weeks course of inhaled Fluticasone (Flixotide®-GlaxoSmithKline Australia) in metered dose inhaler (MDI) with dose of 250 µg 2 puff BID.
Treatment - Drugs
12 weeks course of inhaled Fluticasone (Flixotide®-GlaxoSmithKline Australia) in metered dose inhaler (MDI) with dose of 250 µg 2 puff BID
Sponsors
Vice chancellor for research, Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Study inclusion criteria : 1. high clinical probability of asthma; 2.Normal chest-x-ray; 3.Normal spirometry; 4.Negative methacholine challenge test; 5.Symptoms for at least 2 month; 6.Those who complete treatment course and follow up; Study Exclusion criteria: 1.Low clinical probability of asthma; 2.Abnormality in imaging and spirometry; 3.More than 20 pack year smoking; 4.Prominent medical disease; 5.Significant occupational injury; 6.Those who do not complete treatment course and follow up;
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Asthma Control Test questionnaire Score. Timepoint: 12 weeks. Method of measurement: questionnaire.;Numeric Cough Score. Timepoint: 12 weeks. Method of measurement: questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| General satisfaction of patients. Timepoint: after 12 weeks. Method of measurement: ACT questionnaire (question number 5) score. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Soheil Peiman
Tehran university of medical science, Imamkhomeini medical center
Outcome results
None listed